BYSI
BeyondSpring
No price yet
Announcements
Nothing here yet
Daily updates
- BeyondSpring received FDA Fast Track designation for plinabulin plus docetaxel in second- and third-line advanced or metastatic non-squamous NSCLC without actionable genomic mutations after prior chemoimmunotherapy.Sep 29, 2026
- SEED Therapeutics received FDA Orphan Drug Designation for ST-01156 in neuroblastomaAug 14, 2026
FDA designations
News
- BeyondSpring receives FDA Fast Track Designation for plinabulin in post-ICI non-squamous NSCLC and enters a strategic transaction to advance the global Phase 3 DUBLIN-4 trial toward its planned interim analysisSep 29, 2026
- BeyondSpring announced a leadership transition to support execution of its DUBLIN-4 program and long-term growthJun 4, 2026
- BeyondSpring presents Phase 2 data on pembrolizumab with plinabulin/docetaxel in metastatic NSCLC post first-line immunotherapy at ASCO 2025Jun 3, 2025